Sub-Total: $0.00
Human ERRg Reporter Assay Kit
Product Description and Product Data
This is an all-inclusive cell-based luciferase reporter assay kit targeting the Human Estrogen-Related Receptor Gamma (ERRg). INDIGO’s ERR Gamma reporter assay utilizes proprietary mammalian cells that have been engineered to provide constitutive expression of the ERR Gamma. In addition to ERR Gamma Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user’s test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate. The principal application of this assay is in the screening of test samples to quantify any functional activities, either agonist or inverse-agonist that they may exert against human ERR Gamma. This kit provides researchers with clear, reproducible results, exceptional cell viability post-thaw, and consistent results lot to lot. Kits must be stored at -80C. Do not store in liquid nitrogen. Note: reporter cells cannot be refrozen or maintained in extended culture.
Features
Clear, Reproducible Results
- All-Inclusive Assay Systems
- Exceptional Cell Viability Post-Thaw
- Consistent Results Lot to Lot
Product Specifications
| Target Type | Nuclear Hormone Receptor | ||
| Species | Human | ||
| Receptor Form | Hybrid | ||
| Assay Mode | Inverse Agonist | ||
| Kit Components |
| ||
| Shelf Life | 6 months | ||
| Orthologs Available | No | ||
| Shipping Requirements | Dry Ice | ||
| Storage temperature | -80C |
Data
Target Background
INDIGO’s Estrogen-related Receptor Gamma cell-based assay systems utilize proprietary mammalian cells engineered to provide high-level expression of a hybrid form of Human ERRγ (also known as NR3B3).
Reporter Cells also incorporate a responsive luciferase reporter gene. Quantifying expressed luciferase activity at the assay endpoint provides a sensitive surrogate measure of changes in ERRγ activity in treated cells. As is true in vivo, these reporter cells express ERRγ in a constitutive state of high-level activity in the putative absence of bound ligand. Interestingly, the ligand binding domain of ERRγ may be occupied by a ligand that produces further elevation of the receptor’s constitutive activity (an agonist response). Alternatively, ERRγ may have ligand-binding interactions that results in the loss of constitutive active (an inverse-agonist response).
Therefore, the principle application of this assay system is in the screening of test samples to quantify the agonist or inverse-agonist activities that they may exert against human ERRγ.
Also available as a service
